1H-咪唑-5-丙酸甲酯盐酸盐 | 53958-94-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1H-咪唑-5-丙酸甲酯盐酸盐
• 英文名称: methyl 3-(1H-imidazol-4-yl)propanoate hydrochloride
• 英文别名: methyl 3-(1H-imidazol-5-yl)propanoate;hydrochloride
• CAS: 53958-94-4
• 化学式: C₇H₁₀N₂O₂*ClH
• mdl: MFCD08061575
• 分子量: 190.63
• InChiKey: AITCRIQOLWJSQW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.04
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  55
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1H-咪唑-5-丙酸甲酯盐酸盐 在 lithium aluminium tetrahydride 、 15-冠醚-5 、 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 乙醚 、 乙腈 为溶剂， 反应 38.0h， 生成 3-<1-(triphenylmethyl)imidazol-4(5)-yl>propyl 4-iodobenzyl ether
  参考文献：
  名称：

  10.1021/jm950476

  摘要：

  DOI：

  10.1021/jm950476
• 作为产物：
  描述：

  (E)-3-(1H-咪唑-4-基)丙烯酸甲酯单盐酸盐 在 Pd on carbon 作用下， 以 乙醇 为溶剂， 生成 1H-咪唑-5-丙酸甲酯盐酸盐
  参考文献：
  名称：

  Inhibitors of prenyl-protein transferase

  摘要：

  本发明涉及抑制萜基-蛋白转移酶（FTase）和致癌基因蛋白Ras的大环化合物。该发明还涉及含有本发明化合物的化疗组合物以及抑制萜基-蛋白转移酶和致癌基因蛋白Ras的方法。

  公开号：

  US06441017B1

文献信息

• Preparation of Protected?2- and?3-Homocysteine,?2- and?3-Homohistidine, and?2-Homoserine for Solid-Phase Syntheses
  作者：G�rald Lelais、Peter Micuch、Delphine Josien-Lefebvre、Francesco Rossi、Dieter Seebach

  DOI：10.1002/hlca.200490280

  日期：2004.12

  The Ser, Cys, and His side chains play decisive roles in the syntheses, structures, and functions of proteins and enzymes. For our structural and biomedical investigations of β-peptides consisting of amino acids with proteinogenic side chains, we needed to have reliable preparative access to the title compounds. The two β3-homoamino acid derivatives were obtained by Arndt–Eistert methodology from Boc-His(Ts)-OH

  Ser，Cys和His的侧链在蛋白质和酶的合成，结构和功能中起决定性作用。为了进行由具有蛋白原性侧链的氨基酸组成的β肽的结构和生物医学研究，我们需要可靠地制备标题化合物。两个β 3 -homoamino酸衍生物是通过获得阿恩特-艾斯特方法由Boc-他（TS）-OH和Fmoc-半胱氨酸（PMB）-OH（方案2-4），与侧链官能团的反应性，需要特殊预防措施。该β 2在手性恶唑烷酮辅助DIOZ的帮助下，通过向非对映体选择性地向甲醛（由三恶烷原位生成）中添加合适的Ti-烯醇盐，并随后进行官能团操作，制备高纯氨基酸。这些包括OHO吨卜醚化（对于β 2 hSer;方案5和6），OHSTrt更换（对于β 2个hCys;方案7），和CH 2 OHCH 2 Ñ 3 CH 2 NH 2个变换（对于β 2 hHis;方案9 –11）。包括保护/脱保护/再保护反应在内，从商业前体中获得对映体纯的目标化合物需要多达
• Organic compounds
  申请人：Ksander Michael Gary

  公开号：US20070049616A1

  公开（公告）日：2007-03-01

  The present invention provides a compound of formula I: Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction, gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer and fibrocystic mastopathy. Finally, the present invention also provides a pharmaceutical composition.

  本发明提供了一种I式化合物：所述化合物是醛固酮合成酶和芳香化酶的抑制剂，因此可用于治疗由醛固酮合成酶或芳香化酶介导的疾病或疾病。因此，I式化合物可用于治疗低钾血症、高血压、充血性心力衰竭、心房颤动、肾功能衰竭，特别是慢性肾功能衰竭、再狭窄、动脉粥样硬化、X综合征、肥胖、肾病、心肌梗死后、冠心病、炎症、胶原蛋白增生、纤维化如心脏或心肌纤维化以及高血压和内皮功能障碍后的重塑，男性乳房发育过大、骨质疏松症、前列腺癌、子宫内膜异位症、子宫肌瘤、功能性子宫出血、子宫内膜增生、多囊卵巢综合征、不孕症、纤维囊性乳腺疾病、乳腺癌和纤维囊性乳房病。最后，本发明还提供了一种药物组合物。
• [EN] STABLE GLP-1 BASED GLP-1/GLUCAGON RECEPTOR CO-AGONISTS<br/>[FR] CO-AGONISTES DU RÉCEPTEUR DE GLP-1/GLUCAGON À BASE DE GLP-1 STABLE
  申请人：NOVO NORDISK AS

  公开号：WO2016055610A1

  公开（公告）日：2016-04-14

  The application concerns stable and protracted GLP-1 derivatives which are GLP-l/glucagon receptor co-agonists, compositions thereof, use of the GLP-1 derivatives in medicine, and to methods of treatment comprising administration of the GLP-1 derivatives to patients, including treatment of diabetes, obesity and related diseases and conditions. Prefered GLP-1 derivatives comprise a polypeptide consisting of the amino acid sequence of Formula I: lmp-X8-His-Gly-Thr-Phe-Thr-Ser-Asp-Xl 6-Ser-Xi 8-Tyr-Leu-Glu-X22- X23-Ala-Ala -X26-X27-Phe-I le-Ala-Trp-Leu-X33-X34-X35-X36-X37 [I], wherein - X8 is Ala, Aib, Acb, or Gly; - X16 is Val, Leu, lie, or Tyr; - X18 is Lys or Arg; - X22 is Gly, Ala, Glu, Lys, Arg, Ser, orAib; - X23 is Gin, Arg, or Lys; - X26 is Lys or Arg; - X27 is Glu or Lys; - X33 is Val, Leu, or lle; - X34 is Lys or Arg; - X35 is Gly, Thr, Lys, or is absent; - X36 is Ala, Gly, Lys, Ser, or is absent; - X37 is Gly or is absent; wherein said GLP-i derivative further comprises a substituent comprising a lipophilic moiety and at least two negatively charged moieties, wherein one of said negatively charged moieties is distal of a lipophilic moiety; wherein said polypeptide optionally comprises a C-terminal amide; or a pharmaceutically acceptable salt and/or ester thereof.

  该应用涉及稳定且持久的GLP-1衍生物，这些衍生物是GLP-1/glucagon受体共激动剂，以及其组成成分，将GLP-1衍生物用于医学，以及包括将GLP-1衍生物用于患者治疗的治疗方法，包括治疗糖尿病、肥胖和相关疾病和病况。首选的GLP-1衍生物包括由以下公式I的氨基酸序列组成的多肽：lmp-X8-His-Gly-Thr-Phe-Thr-Ser-Asp-Xl 6-Ser-Xi 8-Tyr-Leu-Glu-X22- X23-Ala-Ala -X26-X27-Phe-I le-Ala-Trp-Leu-X33-X34-X35-X36-X37 [I]，其中 - X8是Ala、Aib、Acb或Gly；- X16是Val、Leu、Ile或Tyr；- X18是Lys或Arg；- X22是Gly、Ala、Glu、Lys、Arg、Ser或Aib；- X23是Gln、Arg或Lys；- X26是Lys或Arg；- X27是Glu或Lys；- X33是Val、Leu或Ile；- X34是Lys或Arg；- X35是Gly、Thr、Lys或不存在；- X36是Ala、Gly、Lys、Ser或不存在；- X37是Gly或不存在；其中所述的GLP-1衍生物进一步包括含有一个亲脂性基团和至少两个负电荷基团的取代基，其中所述的负电荷基团之一远离亲脂性基团；其中所述的多肽可选地包括一个C-末端酰胺；或其药用盐和/或酯。
• [EN] LINEAR APELIN RECEPTOR AGONISTS<br/>[FR] AGONISTES LINÉAIRES DU RÉCEPTEUR DE L'APELINE
  申请人：HEPTARES THERAPEUTICS LTD

  公开号：WO2022079428A1

  公开（公告）日：2022-04-21

  The disclosures herein relate to novel compounds of formula (1): and salts thereof, wherein Q, X, AA1, AA2, AA3, AA4, AA5, AA6, AA7, AA8, AA9, AA10, AA11, AA12, AA13, R1R2and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with Apelin receptors.

  本公开涉及式（1）的新化合物及其盐，其中Q、X、AA1、AA2、AA3、AA4、AA5、AA6、AA7、AA8、AA9、AA10、AA11、AA12、AA13、R1R2和n在此处定义，并其在治疗、预防、改善、控制或减少与Apelin受体相关的疾病风险方面的用途。
• Organic Compounds
  申请人：Ksander Gary Michael

  公开号：US20130287789A1

  公开（公告）日：2013-10-31

  The present invention provides a compound of formula I: Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction, gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer and fibrocystic mastopathy. Finally, the present invention also provides a pharmaceutical composition.

  本发明提供了一种化合物I，其为醛固酮合成酶和芳香化酶的抑制剂，因此可用于治疗由醛固酮合成酶或芳香化酶介导的疾病或疾病。因此，化合物I可用于治疗低钾血症、高血压、充血性心力衰竭、心房颤动、肾衰竭，特别是慢性肾衰竭、再狭窄、动脉粥样硬化、X综合症、肥胖症、肾病、心肌梗死后、冠心病、炎症、胶原形成增加、纤维化如心脏或心肌纤维化以及高血压和内皮功能障碍后的重塑、男性乳腺增生、骨质疏松症、前列腺癌、子宫内膜异位症、子宫肌瘤、功能性子宫出血、子宫内膜增生、多囊卵巢综合症、不孕症、纤维囊性乳房病、乳腺癌和纤维囊性乳房病。最后，本发明还提供了一种制药组合物。